Pancreatic Cancer Trial, Recruiting NCT06539806 Sponsor: Tanta University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06539806
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 50 or older who have been diagnosed with pancreatic cancer
  • People who have high blood pressure, with a reading of 140/90 mmHg or higher
  • People whose pancreatic cancer has been confirmed by laboratory testing of tissue samples, and whose cancer has either spread to other parts of the body or is locally advanced (grown beyond the pancreas but not yet spread widely)
  • People who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • People who have serious ongoing problems with the heart, kidneys, liver, or lungs
  • Women who are pregnant, breastfeeding, or who could become pregnant
  • People who have received a specific type of chemotherapy called a fluoropyrimidine at any point in the last 10 years
  • People who have previously had a severe unexpected reaction to certain chemotherapy medicines, or who have a known allergy to 5-fluorouracil, irinotecan, oxaliplatin, losartan, or any monoclonal antibody treatment (confirm with trial site if unsure which medicines these include)
  • People who have an active, known, or suspected condition where the immune system attacks the body, such as psoriasis
  • People who have tested positive for Hepatitis B, Hepatitis C, HIV, or AIDS
  • People who have received a live or live-attenuated vaccine — such as certain nasal flu vaccines — within 30 days before the planned start of the trial treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Osama Mohamed Hassan, Professor, Clinical Pharmacy Department Faculty of Pharmacy, Tanta University

Phone: +201150232022

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
20 July 2024
Est. completion
10 August 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

the patient response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov